SCHEMBL6627100

SCHEMBL6627100

CC1CNOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11917215 1.00
SCHEMBL22923076 0.65
SCHEMBL17773097 0.63
SCHEMBL16611623 0.62
SCHEMBL21475665 0.62
SCHEMBL1580715 0.62
SCHEMBL1579351 0.62
SCHEMBL16611801 0.62
SCHEMBL219642 0.62
Hydrochloric Acid SCHEMBL950025 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115598941-A Photoresist stripping liquid composition and preparation method thereof 易安爱富科技有限公司(KR) 2023-01-13 CN disclosed
WO-2020203594-A1 FLUORENE DERIVATIVE AND USE THEREOF 日産化学株式会社 2020-10-08 WO disclosed
US-20180215740-A1 PARA-SUBSTITUTED INDANYL AND TETRALINYL DERIVATIVES BASF SE (DE) 2018-08-02 US disclosed
US-10030019-B2 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors FEDORA PHARMACEUTICALS INC. (CA) 2018-07-24 US disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 US disclosed
US-9540370-B2 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) 2017-01-10 US disclosed
US-9393239-B2 Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors FEDORA PHARMACEUTICALS INC. (CA) 2016-07-19 US disclosed
US-20160194320-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS ABBVIE DEUTSCHLAND (DE) 2016-07-07 US disclosed
US-9266855-B2 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors AbbVie Deutschland GmbH & Co. KG (DE) 2016-02-23 US disclosed
US-20160016932-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-21 US disclosed
EP-1435352-A2 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines Wyeth Holdings Corporation (US) 2004-07-07 EP disclosed
EP-0618190-B1 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines WYETH CORP (US) 2004-05-19 EP disclosed
EP-0582829-B1 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines as antibiotic agents AMERICAN CYANAMID CO (US) 2001-09-12 EP disclosed
US-5639742-A ANTIBIOTIC; BACTERICIDE LEE VING JICK (US) 1997-06-17 US disclosed
US-5567692-A CONTROLLING BACTERIA INFECTIONS AMERICAN CYANAMID COMPANY (US) 1996-10-22 US disclosed
US-5495030-A CHEMICAL INTERMEDIATES AMERICAN CYANAMID COMPANY (US) 1996-02-27 US disclosed
US-5442059-A Antibiotics for mammalian and veterninary diseases AMERICAN CYANAMID COMPANY (US) 1995-08-15 US disclosed
US-5371076-A ANTIBIOTICS AMERICAN CYANAMID COMPANY (US) 1994-12-06 US disclosed
EP-0618190-A1 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines AMERICAN CYANAMID COMPANY (US) 1994-10-05 EP disclosed
EP-0582829-A1 9-(substituted glycyl) amido - 6-demethyl-6-deoxytetracyclines as antibiotic agents AMERICAN CYANAMID COMPANY (US) 1994-02-16 EP disclosed